EpiAxis Therapeutics announces new Board member

EpiAxis Therapeutics announces new Board member

EpiAxis Therapeutics is pleased to announce the appointment of Rob McInnes as a non-executive director to the EpiAxis Board, following a successful fund raise supported by Sydney Angels. McInnes is one of Australia’s leading biotech IP specialists having initially...
EpiAxis announces the appointment of three new directors

EpiAxis announces the appointment of three new directors

EpiAxis Therapeutics has appointed Professor Pamela Munster, a highly regarded medical oncologist in the field of metastatic breast cancer and epigenetics; Keir J Loiacono, an oncology focused business development executive and intellectual property specialist; and Dr...
EpiAxis appoints Sage Group to lead global partner search

EpiAxis appoints Sage Group to lead global partner search

EpiAxis has appointed The Sage Group to lead the search for a global strategic partner with whom it can collaborate to exploit its new family of oncology drugs. EpiAxis Therapeutics is a rapidly growing, Australian-based pharmaceutical discovery company leading the...
EpiAxis expands Phase 1 metastic breast cancer trial

EpiAxis expands Phase 1 metastic breast cancer trial

EpiAxis Therapeutics has expanded its clinical trial program to include two additional recruitment centres for its Phase 1b metastatic breast cancer program. The centres open for patient recruitment are the Southern Medical Day Care Centre in Wollongong and at the...